Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology.
Mark L KaytonAaron R WeissWei XueOdion BinitieAndrea Hayes DixonRobert Lor RandallJoel I SorgerDouglas S HawkinsSheri L SpuntDian WangLynn MillionStephanie TerezakisEdwin ChoyScott H OkunoRajkumar VenkatramaniYen-Lin ChenThomas J ScharschmidtPublished in: Journal of surgical oncology (2023)
The addition of pazopanib to neoadjuvant chemotherapy and RT resulted in a higher wound complication rate following therapy of soft tissue sarcoma. The rate of grade III complications remained comparable to that reported in contemporary literature.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- rectal cancer
- soft tissue
- palliative care
- sentinel lymph node
- risk factors
- squamous cell carcinoma
- systematic review
- radiation therapy
- young adults
- surgical site infection
- metastatic renal cell carcinoma
- wound healing
- high grade
- stem cells
- mesenchymal stem cells
- bone marrow